CALRandASXL1mutation analysis in 190 patients with essential thrombocythemia

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

(2014) A Tefferi et al.   LEUKEMIA

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact

(2014) A Tefferi et al.   LEUKEMIA

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

(2013) G. Rotunno et al.   BLOOD

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutation analysis ofASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,andTET2in myeloproliferative neoplasms

(2012) Mandy Brecqueville et al.   GENES CHROMOSOMES & CANCER

Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification

(2012) L. Yan et al.   HAEMATOLOGICA

Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms

(2011) D. Pietra et al.   HAEMATOLOGICA